| Literature DB >> 27039197 |
Jan Szewieczek1, Zbigniew Gąsior2, Jan Duława3, Tomasz Francuz4, Katarzyna Legierska3, Agnieszka Batko-Szwaczka5, Beata Hornik6, Magdalena Janusz-Jenczeń6, Iwona Włodarczyk6, Krzysztof Wilczyński5.
Abstract
We examined the electrocardiographic (ECG) findings of centenarians and associated them with >360-day survival. Physical and functional assessment, resting electrocardiogram and laboratory tests were performed on 86 study participants 101.9 ± 1.2 years old (mean ± SD) (70 women, 16 men) and followed for at least 360 days. Centenarian ECGs were assessed for left ventricular hypertrophy (LVH) according to the Romhilt-Estes score, Sokolow-Lyon criteria and Cornell voltage criteria which were positive for 12.8, 6.98, and 10.5 % of participants, respectively. Fifty-two study participants (60 %) survived ≥360 days. Multivariate logistic regression analysis revealed a negative relationship between 360-day survival and the following: R II <0.45 mV adjusted for CRP (odds ratio (OR) = 0.108, 95 % confidence interval (CI) = 0.034-0.341, P < .001), R aVF < 0.35 mV adjusted for CRP (OR = 0.151, 95 % CI = 0.039-0.584, P < .006), Sokolow-Lyon voltage <1.45 mV adjusted for CRP (OR = 0.178, 95 % CI = 0.064-0.492, P = .001), QRS ≥90 ms adjusted for CRP (OR = 0.375, 95 % CI = 0.144-0.975, P = .044), and Romhilt-Estes score ≥5 points adjusted for sex and Barthel Index (OR = 0.459, 95 % CI = 0.212-0.993, P = .048) in single variable ECG models. QRS voltage correlated positively with systolic and pulse pressure, serum vitamin B12 level, sodium, calcium, phosphorous, TIMP-1, and eGFR. QRS voltage correlated negatively with BMI, WHR, serum leptin, IL-6, TNF-α, and PAI-1 levels. QRS complex duration correlated positively with CRP; QTc correlated positively with TNF-α. Results suggest that Romhilt-Estes LVH criteria scores ≥5 points, low ECG QRS voltages (Sokolow-Lyon voltage <1.45 mV), and QRS complexes ≥90 ms are predictive of centenarian 360-day mortality.Entities:
Keywords: Centenarians; ECG; Left ventricular hypertrophy; Low QRS voltage
Mesh:
Year: 2016 PMID: 27039197 PMCID: PMC5005906 DOI: 10.1007/s11357-016-9907-0
Source DB: PubMed Journal: Age (Dordr) ISSN: 0161-9152
ECG measures in the study group
| Variable | Survivors ( | Nonsurvivors ( | Survivors versus nonsurvivors |
|---|---|---|---|
| Mean ± SD |
| ||
| QRS complex duration (s) | 0.11 ± 0.11 | 0.12 ± 0.14 | 0.045 |
| Ventricular activation time in V1 (s) | 0.03 ± 0.04 | 0.05 ± 0.04 | 0.002 |
| Corrected QT interval (s) | 0.44 ± 0.07 | 0.45 ± 0.03 | 0.045 |
| R wave in the lead II (mV) | 0.56 ± 0.26 | 0.34 ± 0.25 | <0.001 |
| R wave in aVF (mV) | 0.31 ± 0.22 | 0.18 ± 0.14 | 0.005 |
| S wave in V1 (SV1) (mV) | 0.77 ± 0.55 | 0.52 ± 0.49 | 0.020 |
| R wave in V5 (RV5) (mV) | 1.16 ± 0.56 | 0.88 ± 0.52 | 0.031 |
| R wave in V6 (RV6) (mV) | 1.05 ± 0.54 | 0.74 ± 0.42 | 0.012 |
| Maximal R wave in V5 or V6 (mV) | 1.22 ± 0.56 | 0.92 ± 0.51 | 0.023 |
| SV1 + RV5 or RV6 (mV) | 1.99 ± 0.72 | 1.44 ± 0.75 | <0.001 |
| Romhilt–Estes 5. criterion (1 point if QRS duration >0.09 s) (points) | 0.38 ± 0.49 | 0.68 ± 0.48 | 0.023 |
| Romhilt–Estes 5. criterion positive results ( | 20 (38.5) | 23 (67.7) | 0.008 |
| Romhilt–Estes Score (points) | 2.13 ± 2.09 | 3.00 ± 2.32 | 0.063 |
| Romhilt–Estes Score positive results for probable LVH (LVH is likely with 4 or more points) ( | 10 (19.2) | 13 (38.2) | 0.052 |
| Romhilt–Estes Score positive results for LVH (LVH is present with 5 or more points) ( | 4 (7.7) | 7 (20.6) | 0.079 |
Fig. 1Kaplan–Meier survival probability of centenarians classified according to a amplitude of R wave in lead II ≥0.45 mV versus lower values, b amplitude of R wave in lead II ≥0.35 mV versus lower values, c Sokolow–Lyon voltage ≥1.45 mV versus lower values, and d QRS complex duration <90 ms versus higher values
Correlations between clinical or laboratory measures and ECG measures in centenarians (n = 86)
| Clinical and laboratory measures | ECG measures | Spearman’s rank correlation coefficient |
|
|---|---|---|---|
| BMI (body mass index) | R wave in II | −0.213 | 0.049 |
| R wave in V5 | −0.245 | 0.023 | |
| R wave in V5 or V6 | −0.233 | 0.031 | |
| S wave in V1 + R wave in V5 or V6 | −0.242 | 0.024 | |
| WHR (waist to hip ratio) | S wave in V1 + R wave in V5 or V6 | −0.269 | 0.013 |
| Systolic blood pressure | R wave in II | 0.261 | 0.015 |
| R wave in aVF | 0.307 | 0.004 | |
| R wave in V5 | 0.223 | 0.039 | |
| R wave in V5 or V6 | 0.262 | 0.015 | |
| S wave in V1 | 0.250 | 0.020 | |
| S wave in V1 + R wave in V5 or V6 | 0.261 | 0.015 | |
| Pulse pressure | Heart rate | −0.316 | 0.003 |
| R wave in aVF | 0.239 | 0.026 | |
| R wave in V6 | 0.304 | 0.004 | |
| S wave in V1 | 0.316 | 0.003 | |
| S wave in V1 + R wave in V5 or V6 | 0.335 | 0.002 | |
| CRPa | QRS complex duration | 0.216 | 0.049 |
| Ventricular activation time in V1 | 0.302 | 0.005 | |
| Bilirubina | QRS complex duration | 0.256 | 0.019 |
| Vitamin B12a | S wave in V1 | 0.254 | 0.022 |
| Leptinb | R wave in V5 | −0.331 | 0.030 |
| Sodiumc | R wave in II | 0.327 | 0.025 |
| Calciumc | R wave in II | 0.400 | 0.004 |
| R wave in aVF | 0.307 | 0.032 | |
| R wave in V5 | 0.316 | 0.027 | |
| R wave in V6 | 0.299 | 0.037 | |
| S wave in V1 + R wave in V5 or V6 | 0.312 | 0.029 | |
| Phosphorus (inorganic)c | S wave in V1 | 0.447 | 0.001 |
| S wave in V1 + R wave in V5 or V6 | 0.383 | 0.007 | |
| Cornell Voltage value (R wave in aVL + S wave in V3) | 0.445 | 0.001 | |
| eGFR (CKD-EPI creatinine–cystatin C equation) | Heart rate | −0.273 | 0.012 |
| QRS complex duration | −0.237 | 0.030 | |
| eGFR (BIS_creatinine-cystatin C equation) | R wave in aVF | 0.235 | 0.031 |
| Interleukin 6b | R wave in V5 | −0.328 | 0.028 |
| R wave in V6 | −0.317 | 0.034 | |
| R wave in V5 or V6 | −0.333 | 0.025 | |
| S wave in V1 | −0.343 | 0.021 | |
| S wave in V1 + R wave in V5 or V6 | −0.526 | 0.000 | |
| Tumor necrosis factor alphab | Corrected QT interval | 0.307 | 0.040 |
| Plasminogen activator inhibitor-1b | S wave in V1 | −0.347 | 0.023 |
| Cornell Voltage value (R wave in aVL + S wave in V3) | −0.489 | 0.001 | |
| Tissue inhibitor of metalloproteinases 1b | Romhilt–Estes Score | 0.313 | 0.041 |
aSerum level, assessed in 84 subjects
bSerum level, assessed in 43 subjects
cSerum level, assessed in 49 subjects